Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
This study established the activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195 carbapenem-nonsusceptible (CNSPA) clinical isolates recovered from Singapore between 2009 and 2020. C/T susceptibility rates were low, at 37.9%. Cross-r...
Saved in:
Published in | mSphere Vol. 6; no. 1 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
27.01.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | This study established the
activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195 carbapenem-nonsusceptible
(CNSPA) clinical isolates recovered from Singapore between 2009 and 2020. C/T susceptibility rates were low, at 37.9%. Cross-resistance to ceftazidime/avibactam was observed, although susceptibility to the agent was slightly higher, at 41.0%. Whole-genome sequencing revealed that C/T resistance was largely mediated by the presence of horizontally acquired
-lactamases, especially metallo-
-lactamases. These were primarily disseminated in well-recognized high-risk clones belonging to sequence types (ST) 235, 308, and 179. C/T resistance was also observed in several non-carbapenemase-producing isolates, in which resistance was likely mediated by
-lactamases and, to a smaller extent, mutations in AmpC-related genes. There was no obvious mechanism of resistance observed in five isolates. The high C/T resistance highlights the limited utility of the agent as an empirical agent in our setting. Knowledge of local molecular epidemiology is crucial in determining the potential of therapy with novel agents.
infection is one of the most difficult health care-associated infections to treat due to the ability of the organism to acquire a multitude of resistance mechanisms and express the multidrug resistance phenotype. Ceftolozane/tazobactam (C/T), a novel
-lactam/
-lactamase inhibitor combination, addresses an unmet medical need in patients with these multidrug-resistant
infections. Our findings demonstrate geographical variation in C/T susceptibility owing to the distinct local molecular epidemiology. This study adds on to the growing knowledge of C/T resistance, particularly mutational resistance, and will aid in the design of future β-lactams and
-lactamase inhibitors. WGS proved to be a useful tool to understand the
resistome and its contribution to emerging resistance in novel antimicrobial agents. |
---|---|
AbstractList | Pseudomonas aeruginosa
infection is one of the most difficult health care-associated infections to treat due to the ability of the organism to acquire a multitude of resistance mechanisms and express the multidrug resistance phenotype. Ceftolozane/tazobactam (C/T), a novel
β
-lactam/
β
-lactamase inhibitor combination, addresses an unmet medical need in patients with these multidrug-resistant
P. aeruginosa
infections.
This study established the
in vitro
activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195 carbapenem-nonsusceptible
Pseudomonas aeruginosa
(CNSPA) clinical isolates recovered from Singapore between 2009 and 2020. C/T susceptibility rates were low, at 37.9%. Cross-resistance to ceftazidime/avibactam was observed, although susceptibility to the agent was slightly higher, at 41.0%. Whole-genome sequencing revealed that C/T resistance was largely mediated by the presence of horizontally acquired
β
-lactamases, especially metallo-
β
-lactamases. These were primarily disseminated in well-recognized high-risk clones belonging to sequence types (ST) 235, 308, and 179. C/T resistance was also observed in several non-carbapenemase-producing isolates, in which resistance was likely mediated by
β
-lactamases and, to a smaller extent, mutations in AmpC-related genes. There was no obvious mechanism of resistance observed in five isolates. The high C/T resistance highlights the limited utility of the agent as an empirical agent in our setting. Knowledge of local molecular epidemiology is crucial in determining the potential of therapy with novel agents.
IMPORTANCE
Pseudomonas aeruginosa
infection is one of the most difficult health care-associated infections to treat due to the ability of the organism to acquire a multitude of resistance mechanisms and express the multidrug resistance phenotype. Ceftolozane/tazobactam (C/T), a novel
β
-lactam/
β
-lactamase inhibitor combination, addresses an unmet medical need in patients with these multidrug-resistant
P. aeruginosa
infections. Our findings demonstrate geographical variation in C/T susceptibility owing to the distinct local molecular epidemiology. This study adds on to the growing knowledge of C/T resistance, particularly mutational resistance, and will aid in the design of future β-lactams and
β
-lactamase inhibitors. WGS proved to be a useful tool to understand the
P. aeruginosa
resistome and its contribution to emerging resistance in novel antimicrobial agents. This study established the in vitro activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195 carbapenem-nonsusceptible Pseudomonas aeruginosa (CNSPA) clinical isolates recovered from Singapore between 2009 and 2020. C/T susceptibility rates were low, at 37.9%. Cross-resistance to ceftazidime/avibactam was observed, although susceptibility to the agent was slightly higher, at 41.0%. Whole-genome sequencing revealed that C/T resistance was largely mediated by the presence of horizontally acquired β-lactamases, especially metallo-β-lactamases. These were primarily disseminated in well-recognized high-risk clones belonging to sequence types (ST) 235, 308, and 179. C/T resistance was also observed in several non-carbapenemase-producing isolates, in which resistance was likely mediated by β-lactamases and, to a smaller extent, mutations in AmpC-related genes. There was no obvious mechanism of resistance observed in five isolates. The high C/T resistance highlights the limited utility of the agent as an empirical agent in our setting. Knowledge of local molecular epidemiology is crucial in determining the potential of therapy with novel agents. IMPORTANCE Pseudomonas aeruginosa infection is one of the most difficult health care-associated infections to treat due to the ability of the organism to acquire a multitude of resistance mechanisms and express the multidrug resistance phenotype. Ceftolozane/tazobactam (C/T), a novel β-lactam/β-lactamase inhibitor combination, addresses an unmet medical need in patients with these multidrug-resistant P. aeruginosa infections. Our findings demonstrate geographical variation in C/T susceptibility owing to the distinct local molecular epidemiology. This study adds on to the growing knowledge of C/T resistance, particularly mutational resistance, and will aid in the design of future β-lactams and β-lactamase inhibitors. WGS proved to be a useful tool to understand the P. aeruginosa resistome and its contribution to emerging resistance in novel antimicrobial agents. This study established the activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195 carbapenem-nonsusceptible (CNSPA) clinical isolates recovered from Singapore between 2009 and 2020. C/T susceptibility rates were low, at 37.9%. Cross-resistance to ceftazidime/avibactam was observed, although susceptibility to the agent was slightly higher, at 41.0%. Whole-genome sequencing revealed that C/T resistance was largely mediated by the presence of horizontally acquired -lactamases, especially metallo- -lactamases. These were primarily disseminated in well-recognized high-risk clones belonging to sequence types (ST) 235, 308, and 179. C/T resistance was also observed in several non-carbapenemase-producing isolates, in which resistance was likely mediated by -lactamases and, to a smaller extent, mutations in AmpC-related genes. There was no obvious mechanism of resistance observed in five isolates. The high C/T resistance highlights the limited utility of the agent as an empirical agent in our setting. Knowledge of local molecular epidemiology is crucial in determining the potential of therapy with novel agents. infection is one of the most difficult health care-associated infections to treat due to the ability of the organism to acquire a multitude of resistance mechanisms and express the multidrug resistance phenotype. Ceftolozane/tazobactam (C/T), a novel -lactam/ -lactamase inhibitor combination, addresses an unmet medical need in patients with these multidrug-resistant infections. Our findings demonstrate geographical variation in C/T susceptibility owing to the distinct local molecular epidemiology. This study adds on to the growing knowledge of C/T resistance, particularly mutational resistance, and will aid in the design of future β-lactams and -lactamase inhibitors. WGS proved to be a useful tool to understand the resistome and its contribution to emerging resistance in novel antimicrobial agents. Pseudomonas aeruginosaββP. aeruginosa |
Author | Sim, James Heng-Chiak Kwa, Andrea Lay-Hoon Lee, Shannon Jing-Yi Teo, Jocelyn Qi-Min Tang, Cheng Yee Tan, Si Hui Ong, Rick Twee-Hee Lim, Jie Chong |
Author_xml | – sequence: 1 givenname: Jocelyn Qi-Min orcidid: 0000-0003-2508-3941 surname: Teo fullname: Teo, Jocelyn Qi-Min organization: Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore – sequence: 2 givenname: Jie Chong surname: Lim fullname: Lim, Jie Chong organization: Department of Pharmacy, National University of Singapore, Singapore, Singapore – sequence: 3 givenname: Cheng Yee surname: Tang fullname: Tang, Cheng Yee organization: Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore – sequence: 4 givenname: Shannon Jing-Yi surname: Lee fullname: Lee, Shannon Jing-Yi organization: Department of Pharmacy, Singapore General Hospital, Singapore, Singapore – sequence: 5 givenname: Si Hui surname: Tan fullname: Tan, Si Hui organization: Department of Pharmacy, Singapore General Hospital, Singapore, Singapore – sequence: 6 givenname: James Heng-Chiak surname: Sim fullname: Sim, James Heng-Chiak organization: Department of Microbiology, Singapore General Hospital, Singapore, Singapore – sequence: 7 givenname: Rick Twee-Hee surname: Ong fullname: Ong, Rick Twee-Hee email: ephoth@nus.edu.sg, andrea.kwa.l.h@sgh.com.sg organization: Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore ephoth@nus.edu.sg andrea.kwa.l.h@sgh.com.sg – sequence: 8 givenname: Andrea Lay-Hoon orcidid: 0000-0001-8981-4411 surname: Kwa fullname: Kwa, Andrea Lay-Hoon email: ephoth@nus.edu.sg, andrea.kwa.l.h@sgh.com.sg organization: Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore, Singapore |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33504661$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kk1v1DAQhi1URD_onRPKkUta24k_ckFCq4VWaqFqy9ma2JNdrxJ7sRMk-usbdkvVXjh55Hn9zMw7PiYHIQYk5AOjZ4xxfX59d3OxvF2eUUa5LDl9Q454pZpS0JofvIgPyWnOG0opk1xKJd-Rw6qaE1KyI-IW2I2xjw8Q8PweHmILdoShuMXs8wjBYgHBFddo1xB8HnLhQ7GA1MIWAw7l9xjylC1uR9_2WNxknFwcYoBcAKZp5UPM8J687aDPePp0npCfX5f3i4vy6se3y8WXqxIEpWMpmBS6qRvbYFNTRaV0ircdttDSuW-hqVLOsZrXFVNCA6JAhTXTvLUOsatOyOWe6yJszDb5AdIfE8Gb3UVMKwNp9LZHo53oqOBYuUbUgJ22rmO6BqE7hdi4mfV5z9pO7YDOYhgT9K-grzPBr80q_jZKa1FxOgM-PQFS_DVhHs3gZ6P6fnY6TtnwWnMpGtGoWUr3Uptizgm75zKMmr-7NsPddo0JzW7XZkcv908gD9xs4pTC7Oz_9B9fjvNc4N9PqB4BYxa46Q |
CitedBy_id | crossref_primary_10_1128_spectrum_04437_22 crossref_primary_10_1016_j_ajic_2024_02_016 crossref_primary_10_3390_microorganisms10122395 crossref_primary_10_1093_jacamr_dlad070 crossref_primary_10_3390_antibiotics11040517 crossref_primary_10_1093_ofid_ofad173 crossref_primary_10_3390_antibiotics11081101 crossref_primary_10_3390_antibiotics11020193 crossref_primary_10_3390_antibiotics11020130 crossref_primary_10_1007_s10096_021_04308_0 crossref_primary_10_1016_j_ijantimicag_2023_106872 crossref_primary_10_1080_22221751_2021_1968318 crossref_primary_10_1128_spectrum_00766_22 crossref_primary_10_1093_jac_dkac385 crossref_primary_10_3389_fmicb_2024_1385475 crossref_primary_10_1128_AAC_01657_21 crossref_primary_10_1016_j_pathol_2021_12_298 crossref_primary_10_1111_tid_13886 crossref_primary_10_1128_spectrum_01002_23 crossref_primary_10_4102_sajid_v37i1_453 crossref_primary_10_3389_fphar_2022_1007162 crossref_primary_10_1128_spectrum_02700_22 crossref_primary_10_1080_14787210_2022_2071701 crossref_primary_10_1093_cid_ciab390 crossref_primary_10_3390_antibiotics11101432 crossref_primary_10_1128_spectrum_01697_22 crossref_primary_10_1089_fpd_2023_0018 |
Cites_doi | 10.1093/jac/dkx424 10.1093/cid/ciw243 10.1093/cid/cix103 10.1016/j.ijantimicag.2020.105959:105959 10.1128/AAC.01589-17 10.1128/AAC.01310-13 10.3390/microorganisms4010013 10.1016/j.jgar.2019.09.016 10.1016/j.jgar.2017.10.016 10.1016/j.idc.2020.05.001 10.1128/AAC.02462-13 10.1093/cid/ciz830 10.1093/jac/dkz149 10.1128/AAC.03681-14 10.1128/mSystems.00524-19 10.1089/cmb.2012.0021 10.1093/bioinformatics/btv195 10.1128/AAC.02969-15 10.1093/cid/ciaa381 10.1016/j.jgar.2019.12.009 10.1186/s13073-014-0090-6 10.1128/AAC.00825-15 10.1128/AAC.00875-17 10.1016/j.ijantimicag.2009.03.021 10.1093/jac/dkx136 10.1093/bioinformatics/btu170 10.1086/338782 |
ContentType | Journal Article |
Copyright | Copyright © 2021 Teo et al. Copyright © 2021 Teo et al. 2021 Teo et al. |
Copyright_xml | – notice: Copyright © 2021 Teo et al. – notice: Copyright © 2021 Teo et al. 2021 Teo et al. |
DBID | NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.1128/MSPHERE.01026-20 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef PubMed |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2379-5042 |
Editor | Bradford, Patricia A |
Editor_xml | – sequence: 1 givenname: Patricia A surname: Bradford fullname: Bradford, Patricia A – sequence: 1 givenname: Patricia A. surname: Bradford fullname: Bradford, Patricia A. |
ExternalDocumentID | oai_doaj_org_article_8d5f052e3d954aef8cdf184a58f7ee9d 10_1128_mSphere_01026_20 mSphere01026-20 33504661 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: R01 GM112017 – fundername: MOH | National Medical Research Council (NMRC) grantid: CG/C005/2017; CG/M011/2017; TA/0056/2017; NMRC/MOH324 000018-00 funderid: https://doi.org/10.13039/501100001349 – fundername: ; grantid: CG/C005/2017; CG/M011/2017; TA/0056/2017; NMRC/MOH324 000018-00 |
GroupedDBID | 0R~ 3V. 53G 5VS 7X7 8FE 8FH 8FI 8FJ AAFWJ AAUOK ABUWG ADBBV AFKRA AFPKN ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU DIK EBS FRP FYUFA GROUPED_DOAJ H13 HCIFZ HMCUK HYE KQ8 LK8 M48 M7P M~E NPM O9- OK1 PGMZT PIMPY PQQKQ PROAC R9- RHF RHI RPM RSF UKHRP 0R ADACO BBAFP BXI PQEST PQUKI PRINS AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-a500t-51658949c9e9407066d72bfebab067658077dd142431758aee5e7e4182bcdeef3 |
IEDL.DBID | RPM |
ISSN | 2379-5042 |
IngestDate | Tue Oct 22 14:57:43 EDT 2024 Tue Sep 17 21:16:14 EDT 2024 Sat Aug 17 01:51:09 EDT 2024 Fri Dec 06 02:04:30 EST 2024 Tue Dec 28 13:59:17 EST 2021 Sat Sep 28 08:29:58 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | ceftolozane/tazobactam Pseudomonas aeruginosa molecular characterization |
Language | English |
License | Copyright © 2021 Teo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a500t-51658949c9e9407066d72bfebab067658077dd142431758aee5e7e4182bcdeef3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Present address: Shannon Jing-Yi Lee, NovogeneAIT Genomics Singapore Pte Ltd., Singapore, Singapore. Jocelyn Qi-Min Teo and Jie Chong Lim contributed equally to this work. Author order was determined by random coin toss. Rick Twee-Hee Ong and Andrea Lay-Hoon Kwa also contributed equally to this work. Citation Teo JQ, Lim JC, Tang CY, Lee SJ, Tan SH, Sim JH, Ong RT, Kwa AL. 2021. Ceftolozane/tazobactam resistance and mechanisms in carbapenem-nonsusceptible Pseudomonas aeruginosa. mSphere 6:e01026-20. https://doi.org/10.1128/mSphere.01026-20. |
ORCID | 0000-0001-8981-4411 0000-0003-2508-3941 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885320/ |
PMID | 33504661 |
PQID | 2482659597 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_8d5f052e3d954aef8cdf184a58f7ee9d pubmedcentral_primary_oai_pubmedcentral_nih_gov_7885320 proquest_miscellaneous_2482659597 crossref_primary_10_1128_mSphere_01026_20 asm2_journals_10_1128_mSphere_01026_20 pubmed_primary_33504661 |
PublicationCentury | 2000 |
PublicationDate | 20210127 |
PublicationDateYYYYMMDD | 2021-01-27 |
PublicationDate_xml | – month: 1 year: 2021 text: 20210127 day: 27 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
PublicationTitle | mSphere |
PublicationTitleAbbrev | mSphere |
PublicationTitleAlternate | mSphere |
PublicationYear | 2021 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | Grupper, M, Sutherland, C, Nicolau, DP (B7) 2017; 61 Castanheira, M, Mills, JC, Farrell, DJ, Jones, RN (B15) 2014; 58 Livermore, DM (B2) 2002; 34 Kresken, M, Korber-Irrgang, B, Korte-Berwanger, M, Pfennigwerth, N, Gatermann, SG, Seifert, H (B8) 2020; 55 Cabot, G, Bruchmann, S, Mulet, X, Zamorano, L, Moya, B, Juan, C, Haussler, S, Oliver, A (B4) 2014; 58 Doi, Y (B21) 2019; 69 Karlowsky, JA, Lob, SH, Raddatz, J, DePestel, DD, Young, K, Motyl, MR, Sahm, DF (B11) 2020 Skoglund, E, Ledesma, KR, Lasco, TM, Tam, VH (B9) 2017; 11 Cai, Y, Venkatachalam, I, Tee, NW, Tan, TY, Kurup, A, Wong, SY, Low, CY, Wang, Y, Lee, W, Liew, YX, Ang, B, Lye, DC, Chow, A, Ling, ML, Oh, HM, Cuvin, CA, Ooi, ST, Pada, SK, Lim, CH, Tan, JWC, Chew, KL, Nguyen, VH, Fisher, DA, Goossens, H, Kwa, AL, Tambyah, PA, Hsu, LY, Marimuthu, K (B1) 2017; 64 Del Barrio-Tofino, E, Lopez-Causape, C, Cabot, G, Rivera, A, Benito, N, Segura, C, Montero, MM, Sorli, L, Tubau, F, Gomez-Zorrilla, S, Tormo, N, Dura-Navarro, R, Viedma, E, Resino-Foz, E, Fernandez-Martinez, M, Gonzalez-Rico, C, Alejo-Cancho, I, Martinez, JA, Labayru-Echverria, C, Duenas, C, Ayestaran, I, Zamorano, L, Martinez-Martinez, L, Horcajada, JP, Oliver, A (B12) 2017; 61 Mirza, HC, Hortaç, E, Koçak, AA, Demirkaya, MH, Yayla, B, Güçlü, AÜ, Başustaoğlu, A (B10) 2020; 20 Torrens, G, Hernandez, SB, Ayala, JA, Moya, B, Juan, C, Cava, F, Oliver, A (B22) 2019; 4 Choi, Y, Chan, AP (B29) 2015; 31 Inouye, M, Dashnow, H, Raven, L-A, Schultz, MB, Pope, BJ, Tomita, T, Zobel, J, Holt, KE (B27) 2014; 6 Livermore, DM, Mushtaq, S, Ge, Y, Warner, M (B19) 2009; 34 Wang, Y, Wang, J, Wang, R, Cai, Y (B20) 2020; 22 van Duin, D, Bonomo, RA (B5) 2016; 63 (B23) 2020 Buehrle, DJ, Shields, RK, Chen, L, Hao, B, Press, EG, Alkrouk, A, Potoski, BA, Kreiswirth, BN, Clancy, CJ, Nguyen, MH (B6) 2016; 60 Livermore, DM, Mushtaq, S, Meunier, D, Hopkins, KL, Hill, R, Adkin, R, Chaudhry, A, Pike, R, Staves, P, Woodford, N (B18) 2017; 72 Gupta, SK, Padmanabhan, BR, Diene, SM, Lopez-Rojas, R, Kempf, M, Landraud, L, Rolain, J-M (B28) 2014; 58 Andrews, S (B25) 2010 Ortiz de la Rosa, JM, Nordmann, P, Poirel, L (B14) 2019; 74 Bolger, AM, Lohse, M, Usadel, B (B24) 2014; 30 Fraile-Ribot, PA, Cabot, G, Mulet, X, Perianez, L, Martin-Pena, ML, Juan, C, Perez, JL, Oliver, A (B13) 2018; 73 Berrazeg, M, Jeannot, K, Ntsogo Enguene, VY, Broutin, I, Loeffert, S, Fournier, D, Plesiat, P (B16) 2015; 59 Papp-Wallace, KM, Mack, AR, Taracila, MA, Bonomo, RA (B17) 2020 Bankevich, A, Nurk, S, Antipov, D, Gurevich, AA, Dvorkin, M, Kulikov, AS, Lesin, VM, Nikolenko, SI, Pham, S, Prjibelski, AD, Pyshkin, AV, Sirotkin, AV, Vyahhi, N, Tesler, G, Alekseyev, MA, Pevzner, PA (B26) 2012; 19 Teo, JQ, Cai, Y, Lim, TP, Tan, TT, Kwa, AL (B3) 2016; 4 e_1_3_2_27_2 e_1_3_2_28_2 e_1_3_2_29_2 e_1_3_2_20_2 e_1_3_2_21_2 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_25_2 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_10_2 CLSI (e_1_3_2_24_2) 2020 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_2_2 e_1_3_2_14_2 Andrews S (e_1_3_2_26_2) 2010 |
References_xml | – volume: 73 start-page: 658 year: 2018 end-page: 663 ident: B13 article-title: Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkx424 contributor: fullname: Oliver, A – volume: 63 start-page: 234 year: 2016 end-page: 241 ident: B5 article-title: Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation beta-lactam/beta-lactamase inhibitor combinations publication-title: Clin Infect Dis doi: 10.1093/cid/ciw243 contributor: fullname: Bonomo, RA – volume: 64 start-page: S61 year: 2017 end-page: S67 ident: B1 article-title: Prevalence of healthcare-associated infections and antimicrobial use among adult inpatients in Singapore acute-care hospitals: results from the First National Point Prevalence Survey publication-title: Clin Infect Dis doi: 10.1093/cid/cix103 contributor: fullname: Marimuthu, K – volume: 55 start-page: 105959 year: 2020 ident: B8 article-title: Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2020.105959:105959 contributor: fullname: Seifert, H – volume: 61 year: 2017 ident: B12 article-title: Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01589-17 contributor: fullname: Oliver, A – volume: 58 start-page: 212 year: 2014 end-page: 220 ident: B28 article-title: ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01310-13 contributor: fullname: Rolain, J-M – volume: 4 start-page: 13 year: 2016 ident: B3 article-title: Carbapenem resistance in Gram-negative bacteria: the not-so-little problem in the little red dot publication-title: Microorganisms doi: 10.3390/microorganisms4010013 contributor: fullname: Kwa, AL – volume: 20 start-page: 334 year: 2020 end-page: 338 ident: B10 article-title: In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: a two-centre study publication-title: J Glob Antimicrob Resist doi: 10.1016/j.jgar.2019.09.016 contributor: fullname: Başustaoğlu, A – volume: 11 start-page: 154 year: 2017 end-page: 155 ident: B9 article-title: Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates publication-title: J Glob Antimicrob Resist doi: 10.1016/j.jgar.2017.10.016 contributor: fullname: Tam, VH – year: 2020 ident: B17 article-title: Resistance to novel beta-lactam-beta-lactamase inhibitor combinations: the “price of progress.” publication-title: Infect Dis Clin North Am doi: 10.1016/j.idc.2020.05.001 contributor: fullname: Bonomo, RA – volume: 58 start-page: 3091 year: 2014 end-page: 3099 ident: B4 article-title: Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02462-13 contributor: fullname: Oliver, A – volume: 69 start-page: S565 year: 2019 end-page: S575 ident: B21 article-title: Treatment options for carbapenem-resistant Gram-negative bacterial infections publication-title: Clin Infect Dis doi: 10.1093/cid/ciz830 contributor: fullname: Doi, Y – volume: 74 start-page: 1934 year: 2019 end-page: 1939 ident: B14 article-title: ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkz149 contributor: fullname: Poirel, L – volume: 58 start-page: 6844 year: 2014 end-page: 6850 ident: B15 article-title: Mutation-driven beta-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.03681-14 contributor: fullname: Jones, RN – volume: 4 year: 2019 ident: B22 article-title: Regulation of AmpC-driven beta-lactam resistance in Pseudomonas aeruginosa: different pathways, different signaling publication-title: mSystems doi: 10.1128/mSystems.00524-19 contributor: fullname: Oliver, A – volume: 19 start-page: 455 year: 2012 end-page: 477 ident: B26 article-title: SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing publication-title: J Comput Biol doi: 10.1089/cmb.2012.0021 contributor: fullname: Pevzner, PA – volume: 31 start-page: 2745 year: 2015 end-page: 2747 ident: B29 article-title: PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels publication-title: Bioinformatics doi: 10.1093/bioinformatics/btv195 contributor: fullname: Chan, AP – volume: 60 start-page: 3227 year: 2016 end-page: 3231 ident: B6 article-title: Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02969-15 contributor: fullname: Nguyen, MH – year: 2020 ident: B11 article-title: In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of Gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes—SMART United States 2015–2017 publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa381 contributor: fullname: Sahm, DF – volume: 22 start-page: 18 year: 2020 end-page: 27 ident: B20 article-title: Resistance to ceftazidime-avibactam and underlying mechanisms publication-title: J Glob Antimicrob Resist doi: 10.1016/j.jgar.2019.12.009 contributor: fullname: Cai, Y – volume: 6 start-page: 90 year: 2014 ident: B27 article-title: SRST2: rapid genomic surveillance for public health and hospital microbiology labs publication-title: Genome Med doi: 10.1186/s13073-014-0090-6 contributor: fullname: Holt, KE – volume: 59 start-page: 6248 year: 2015 end-page: 6255 ident: B16 article-title: Mutations in beta-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00825-15 contributor: fullname: Plesiat, P – year: 2020 ident: B23 publication-title: Performance standards for antimicrobial susceptibility testing ;30th ed ;CLSI ;Wayne, PA – year: 2010 ident: B25 publication-title: FastQC: a quality control tool for high throughput sequence data ;Babraham Bioinformatics, Babraham Institute ;Cambridge, United Kingdom contributor: fullname: Andrews, S – volume: 61 year: 2017 ident: B7 article-title: Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00875-17 contributor: fullname: Nicolau, DP – volume: 34 start-page: 402 year: 2009 end-page: 406 ident: B19 article-title: Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2009.03.021 contributor: fullname: Warner, M – volume: 72 start-page: 2278 year: 2017 end-page: 2289 ident: B18 article-title: Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkx136 contributor: fullname: Woodford, N – volume: 30 start-page: 2114 year: 2014 end-page: 2120 ident: B24 article-title: Trimmomatic: a flexible trimmer for Illumina sequence data publication-title: Bioinformatics doi: 10.1093/bioinformatics/btu170 contributor: fullname: Usadel, B – volume: 34 start-page: 634 year: 2002 end-page: 640 ident: B2 article-title: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? publication-title: Clin Infect Dis doi: 10.1086/338782 contributor: fullname: Livermore, DM – ident: e_1_3_2_7_2 doi: 10.1128/AAC.02969-15 – ident: e_1_3_2_10_2 doi: 10.1016/j.jgar.2017.10.016 – ident: e_1_3_2_15_2 doi: 10.1093/jac/dkz149 – ident: e_1_3_2_17_2 doi: 10.1128/AAC.00825-15 – volume-title: FastQC: a quality control tool for high throughput sequence data year: 2010 ident: e_1_3_2_26_2 contributor: fullname: Andrews S – ident: e_1_3_2_23_2 doi: 10.1128/mSystems.00524-19 – ident: e_1_3_2_29_2 doi: 10.1128/AAC.01310-13 – ident: e_1_3_2_3_2 doi: 10.1086/338782 – ident: e_1_3_2_5_2 doi: 10.1128/AAC.02462-13 – ident: e_1_3_2_12_2 doi: 10.1093/cid/ciaa381 – ident: e_1_3_2_6_2 doi: 10.1093/cid/ciw243 – ident: e_1_3_2_27_2 doi: 10.1089/cmb.2012.0021 – ident: e_1_3_2_4_2 doi: 10.3390/microorganisms4010013 – ident: e_1_3_2_20_2 doi: 10.1016/j.ijantimicag.2009.03.021 – ident: e_1_3_2_19_2 doi: 10.1093/jac/dkx136 – ident: e_1_3_2_28_2 doi: 10.1186/s13073-014-0090-6 – ident: e_1_3_2_25_2 doi: 10.1093/bioinformatics/btu170 – ident: e_1_3_2_2_2 doi: 10.1093/cid/cix103 – ident: e_1_3_2_22_2 doi: 10.1093/cid/ciz830 – ident: e_1_3_2_8_2 doi: 10.1128/AAC.00875-17 – ident: e_1_3_2_9_2 doi: 10.1016/j.ijantimicag.2020.105959:105959 – ident: e_1_3_2_11_2 doi: 10.1016/j.jgar.2019.09.016 – ident: e_1_3_2_13_2 doi: 10.1128/AAC.01589-17 – volume-title: Performance standards for antimicrobial susceptibility testing year: 2020 ident: e_1_3_2_24_2 contributor: fullname: CLSI – ident: e_1_3_2_30_2 doi: 10.1093/bioinformatics/btv195 – ident: e_1_3_2_18_2 doi: 10.1016/j.idc.2020.05.001 – ident: e_1_3_2_16_2 doi: 10.1128/AAC.03681-14 – ident: e_1_3_2_14_2 doi: 10.1093/jac/dkx424 – ident: e_1_3_2_21_2 doi: 10.1016/j.jgar.2019.12.009 |
SSID | ssj0001626676 |
Score | 2.3531518 |
Snippet | This study established the
activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195... This study established the in vitro activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195... Pseudomonas aeruginosa infection is one of the most difficult health care-associated infections to treat due to the ability of the organism to acquire a... Pseudomonas aeruginosaββP. aeruginosa |
SourceID | doaj pubmedcentral proquest crossref asm2 pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
SubjectTerms | Clinical Science and Epidemiology Research Article |
SummonAdditionalLinks | – databaseName: American Society for Microbiology Open Access dbid: AAUOK link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZKKyQuiPIMj8pICIlD2qxjx_ZxWbWqQBQEXak3axxPYCWSrerdA_31jLPZha0qxDVOZGu-GfubeB6MvQGiqLWEkFsfUkoOqtwq63Ohw0gbqEaIfbTFWXU6lR8u1MUOU-tcmEGC8RBi21_kbyxbmKP2W0q1x8NUB60ifO-wPVIhST7X3ng8_fzxz88VoumV3lxL3vIp7cA0g9g6jfqi_bcxzZsBk3-dQCcP2P2BOvLxCut9toPdQ3Z31Uzy1yMWJtikZrTX0OHROVyTodYLaPlXjIkjErgcusA_Ycr1ncU28lnHJ-m64ZL2uzY_S8mYsY9y8T-Rf4m4DHNSUogc8Gr5fdbNIzxm05Pj88lpPvRQyFOrg0WuRkQxrLS1RUu-GxGMoIVv0IOnc4rGCq1DSOluiUgYQFSoUZLX4euA2JRP2G437_AZ41VTeii0VQV4WSsJRYq3glLQflpgwIy9TSJ1awhd718I4wbZu172ThQZe7cWurtc1dT4x7vvEyqb91I17P4B6YYbjMuZoJpCCSyDpWVhY-rQkOcKyjQa0YaMvV5j6sh60pUIQTFfRickuVeKtFNn7OkK481UZakKSfQlY3oL_a21bI90sx99hW5tTGq48fx_JfKC3RMpVqYYkZG8ZLuLqyW-IrKz8AeDav8GE1r-5Q priority: 102 providerName: American Society for Microbiology – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA4yIHgR37YvIojgoZ1MutNJjjq4LIKL6C7sLSSdah2we5bNzMH99Vale4cZEb147QQS6qtKvurUg7FXHilqW_tY2hApJQdUaZUNpdRxoY1vFgA52uKkOT6rP56r871WXxQTNpYHHgU3N1F1QkmoolW1h860sUOvxCvTaQAb8-kr5J4zlf-uIE9v9O5dUpp5_5XS9OEt1VBrSmrvPfOplwfXUa7a_yeq-XvE5N4VdHSH3Z64I3837vkuuwHDPXZz7Cb58z6LS-ioG-2VH2B-6q_QUtuN7_kXSEQSEV3uh8g_ASX7rlKf-GrgS3pvuMADry9PKBsz5TCX8AP45wTbuEYt9Yl7uNx-Ww3r5B-ws6MPp8vjcmqiUFKvg02pFsgxbG1bCxadN2QYUcvQQfABLyocE1rHSPluxCSMB1CgoUa3I7QRoKsestmwHuAx401XBS-0VcKHukU0BAVc-UrigSogQsFek0jdZAXJZQdDGjfJ3mXZOykK9uZa6O5iLKrxl7nvCZXdPCqHnT-gkrhJSdy_lKRgL68xdWg-9CaCUKy3ycka_SuF6qkL9mjEeLdUVSlRI38pmD5A_2AvhyPD6nsu0a2NoY4bT_7H5p-yW5ICacQCLegZm20ut_AcmdAmvMhK_wtSkQor priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEF-0ovRF6mejVSKI4EPa3CabzT6I6GEpQotoD_q27GYn9aBJ2ts7aPvXO7PJnZ4cPvia3SXL_mYyv8nOB2NvDVLUKjcuUdZRSg6IRAllEy7dSJamGAGEaIuT4miSfz0TZ7_To4cD9BtdO-onNZld7F9f3XxEhf_QJ8CUB80PysCHfSqPViDsd9k9jnaRAryOB7If_rggdy_k6q5yw8Jt9iDLBHqMoWS28Q1fs1ahqP8mJvp3QOUfFupwhz0cqGX8qZeFR-wOtI_Z_b7Z5M0T5sZQU7PaW9PCwam5RUWu5qaJv4MnDongx6Z18TFQLvDUNz6etvGYriPwQKBJTihZ04coGHsB8TcPC9ehEBsfG5gtzqdt581TNjn8cjo-SoYeCwm1QpgnYoQUROWqUqDQt0MC4iS3NVhj0Y7hWCqlc5QOR0SjNAACJOToldjKAdTZM7bVdi3ssrioM2tSqURqbF6J3KQUj2Uyjt_bFBxE7B0dqV5irIP_wUs9wKADDJqnEXu_PHR92dfc-Mfcz4TKah5Vyw4Putm5HpRPl07UqeCQOYXbgrqsXI2erRFlLQGUi9ibJaYatYuuTBCKbuE1z9H9Eii9MmLPe4xXr1qKSsTkGvpre1kfaac_QwVvWZbUkOPFf698ybY5BdekI9SqPbY1ny3gFbKjuX0dhP4XV1sRfw priority: 102 providerName: Scholars Portal |
Title | Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33504661 https://journals.asm.org/doi/10.1128/mSphere.01026-20 https://search.proquest.com/docview/2482659597 https://pubmed.ncbi.nlm.nih.gov/PMC7885320 https://doaj.org/article/8d5f052e3d954aef8cdf184a58f7ee9d |
Volume | 6 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtx0Zfxr7nfQQPxmAPjh3ZsuzHNLSUjWShayBvQrLOraG2Q5Q8rH_9ToodmjH2sBcbLBkL3Z31O-l3d4R8lghRi0TqIFfahuQAC3KWq4ByPeKZTEcAjm0xSy8XybclWx4R1sfCONJ-oaphc1cPm-rWcStXdRH2PLFwPp2g22brGYTH5BiX3wcuuttYQYie8v2RJM3C-qeN0IehTZ-WolqckidxzNAxdJmxpanpwaLkcvf_DXD-yZt8sBBdPCNPOwTpj3cjfU6OoHlBHu9qSv56SfQESluT9l42EF7Le7TXYiNr_wqMhYooY1822p-CDfmtTG38qvEn9tRhhb-9OpjZmEzjyC7qDvy5ga1uUVel8SWstzdV0xr5iiwuzq8nl0FXSiGwFQ82ARsh0siTvMghRxcOcYbmVJWgpMLlCtsizrW2UW8WT2QSgAGHBJ0PVWiAMn5NTpq2gbfET8tYyYjnLJIqKVgiI0u7kjHF32oEGjzyxU6p6GzBCOdm0Ex0YhBODIJGHvnaT7pY7VJr_KPvmZXKvp9Niu0etOsb0amGyDQrI0Yh1jkOC8qs0CU6sJJlJQfItUc-9TIVaET2ZARF0W6NoAl6WQyVlHvkzU7G-0_1quIRfiD9g7EctqDeukTdnZ6---8335NTajk00QiN5wM52ay38BFB0EYNUPWXfEAejceLH9_xfnY-m18N3JYCXqdJNnBm8RvDQQ8f |
link.rule.ids | 230,314,727,780,784,864,885,2102,24318,27924,27925,31720,33745,53147,53160,53173,53791,53793 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nj9MwELWWRcBeEF8L5TNICIlDmsSJ4_gIFasC22oFXWlvlh1PlkibpKrbA_vrGbtJtUWIA9fEUSy_mfhN_GaGkHcKKWqZKRMKbVxKDrBQMKFDyk3CC5UnAF5tMc-n59nXC3ZxQNiQC-NF-6Wux-1VM27rn15buWzKaNCJRWezCYZtrp9BdIvcZikXyY0g3f9aQZKe892hJC2i5ofL0YexK6CWo2EckbtpyjA09LWxlW3o3rbkq_f_jXL-qZy8sRWdPCD3ew4ZfNzO9SE5gPYRubPtKvnrMTETqFxX2mvVQrRQ1-ix5Vo1wXewjiwiyoFqTTADl_Rb28YGdRtM3LnDEj98TTh3WZnWy130FQRnFjamQ2tVNlCw2lzWbWfVE3J-8nkxmYZ9M4XQ9TxYhyxBriEyUQoQGMQh0zCc6gq00rhh4b2Yc2Nc3ptjFIUCYMAhw_BDlwagSo_JYdu18IwEeZVqFXPBYqWzkmUqdsIrlVL8sMZgYETeuyWVvTdY6QMNWsgeBulhkDQekQ_DosvltrjGP8Z-cqjsxrmy2P5Ct7qUvXHIwrAqZhRSI3BaUBWlqTCEVayoOIAwI_J2wFSiG7mzEYSi21hJM4yzGJopH5GnW4x3rxpMZUT4Hvp7c9m_g5brS3X3lvr8v598Q-5NF7NTefpl_u0FOaJOURMn6EovyeF6tYFXSInW-rV3gN848QyQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLZgiGmXafwODAgSQuKQJnXiOD5uhWr8WFXBJu1m2fHLiLQkVd0etr-eZzetWoQ4cI0dxfL7bH8v_t57hLxXSFHLTJlIaONCcoBFggkdUW6GvFD5EMCrLSb52WX29YpdbZX68qL9UteD9qYZtPUvr62cNWW81onF0_MRum2unkE8M1V8nzxgKYJsy1H3v1eQqOd8czFJi7j56eL0YeCSqOUIjgOyn6YM3UOfH1vZhu4cTT6D_99o55_qya3jaHxEDnseGZ6sxvuI3IP2MXm4qix5-4SYEVSuMu2daiG-UHe4asuFasIfYB1hREuHqjXhObjA39o2NqzbcOTuHma4-TXRxEVmWi950TcQTi0sTYeIVTZUMF9e121n1VNyOf58MTqL-oIKkat7sIjYEPmGyEQpQKAjh2zDcKor0ErjoYVtCefGuNg3xyoKBcCAQ4YuiC4NQJU-I3tt18ILEuZVqlXCBUuUzkqWqcSJr1RKcXNNwEBAPrgplf2KsNI7G7SQvRmkN4OkSUA-riddzlYJNv7R99RZZdPPpcb2D7r5tewBIgvDqoRRSI3AYUFVlKZCN1axouIAwgTk3dqmEpeSux9BU3RLK2mGvhZDqPKAPF_ZePOpNVQCwnesvzOW3RZEr0_X3aP15X-_-ZbsTz-N5fcvk2-vyAF1oppkiKvpmOwt5kt4jaxood94_P8GB9INow |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ceftolozane%2FTazobactam+Resistance+and+Mechanisms+in+Carbapenem-Nonsusceptible+Pseudomonas+aeruginosa&rft.jtitle=mSphere&rft.au=Teo%2C+Jocelyn+Qi-Min&rft.au=Lim%2C+Jie+Chong&rft.au=Tang%2C+Cheng+Yee&rft.au=Lee%2C+Shannon+Jing-Yi&rft.date=2021-01-27&rft.pub=American+Society+for+Microbiology&rft.eissn=2379-5042&rft.volume=6&rft.issue=1&rft_id=info:doi/10.1128%2FmSphere.01026-20&rft_id=info%3Apmid%2F33504661&rft.externalDBID=PMC7885320 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2379-5042&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2379-5042&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2379-5042&client=summon |